Antibody-based targeting of CD24 enhances antitumor effect of cetuximab via attenuating phosphorylation of Src/STAT3.

[1]  Vicki Sifniotis,et al.  The state‐of‐play and future of antibody therapeutics☆ , 2017, Advanced drug delivery reviews.

[2]  Hua He,et al.  A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging. , 2015, Immunobiology.

[3]  D. Condorelli,et al.  In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells , 2014, Cell proliferation.

[4]  H. Hsieh,et al.  Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer , 2014, Expert opinion on investigational drugs.

[5]  Minsoon Kim,et al.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.

[6]  Jun Ma,et al.  Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma , 2014, Molecular Cancer Therapeutics.

[7]  Helen X. Chen,et al.  Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients , 2014, Investigational New Drugs.

[8]  A. Stemmer-Rachamimov,et al.  EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors , 2014, Oncogene.

[9]  R. Carpenter,et al.  STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3 , 2013, Molecular carcinogenesis.

[10]  S. Tsao,et al.  Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor , 2013, Molecular Cancer Therapeutics.

[11]  G. Stark,et al.  STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor , 2013, Proceedings of the National Academy of Sciences.

[12]  R. Hynes,et al.  Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells , 2013, International journal of cancer.

[13]  H. Kato,et al.  CD24 expression is associated with progression of gastric cancer. , 2013, Hepato-gastroenterology.

[14]  R. Mantovani,et al.  EGFR through STAT3 modulates ΔN63α expression to sustain tumor‐initiating cell proliferation in squamous cell carcinomas , 2013, Journal of cellular physiology.

[15]  T. Schlange,et al.  Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas , 2013, British Journal of Cancer.

[16]  R. Kirk.  Targeted therapies: STAT3 and EGFR target resistance , 2012, Nature Reviews Clinical Oncology.

[17]  T. Schlange,et al.  CD24 controls Src/STAT3 activity in human tumors , 2012, Cellular and Molecular Life Sciences.

[18]  R. Kontermann.  Dual targeting strategies with bispecific antibodies , 2012, mAbs.

[19]  H. Allgayer,et al.  CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion , 2011, Cellular and Molecular Life Sciences.

[20]  G. Kristiansen,et al.  CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. , 2011, Cancer research.

[21]  G. Wakabayashi,et al.  Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models , 2011, BMC Research Notes.

[22]  C. Riley,et al.  Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas , 2008, British Journal of Cancer.

[23]  Arnaud M. Vigneron,et al.  The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. , 2008, Cancer research.

[24]  H. Poulsen,et al.  EGFR induces expression of IRF‐1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells , 2008, International journal of cancer.

[25]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[26]  Qiang Wang,et al.  ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.

[27]  Suyun Huang.  Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications , 2007, Clinical Cancer Research.

[28]  T. Morimoto,et al.  Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. , 2006, International journal of oncology.

[29]  V. Schini-Kerth,et al.  Delphinidin and cyanidin inhibit PDGFAB‐induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK , 2006, British journal of pharmacology.

[30]  J. Sleeman,et al.  CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. , 2005, Cancer research.

[31]  J. Baselga,et al.  Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Jänne,et al.  Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations , 2005 .

[33]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[34]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[35]  E. Van Cutsem,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[36]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[37]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Dan Yang,et al.  Cooperation of STAT-1 and IRF-1 in Interferon-γ-induced Transcription of the gp91 phox Gene* , 2002, The Journal of Biological Chemistry.

[39]  M. R. Hough,et al.  Mapping of CD24 and homologous sequences to multiple chromosomal loci. , 1994, Genomics.

[40]  Y. Yarden,et al.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.